Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
BIOD's Cash to Debt is ranked higher than
94% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. BIOD: No Debt )
BIOD' s 10-Year Cash to Debt Range
Min: 34.94   Max: No Debt
Current: No Debt

Interest Coverage No Debt
BIOD's Interest Coverage is ranked higher than
92% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIOD: No Debt )
BIOD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -9.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -69.41
BIOD's ROE (%) is ranked higher than
60% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. BIOD: -69.41 )
BIOD' s 10-Year ROE (%) Range
Min: -1034.56   Max: -34.65
Current: -69.41

-1034.56
-34.65
ROA (%) -58.69
BIOD's ROA (%) is ranked higher than
58% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. BIOD: -58.69 )
BIOD' s 10-Year ROA (%) Range
Min: -566.19   Max: -28.58
Current: -58.69

-566.19
-28.58
ROC (Joel Greenblatt) (%) -3135.84
BIOD's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. BIOD: -3135.84 )
BIOD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2547.75   Max: -884.48
Current: -3135.84

-2547.75
-884.48
EBITDA Growth (3Y)(%) -10.90
BIOD's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. BIOD: -10.90 )
BIOD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 51.6
Current: -10.9

0
51.6
EPS Growth (3Y)(%) -21.40
BIOD's EPS Growth (3Y)(%) is ranked higher than
66% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. BIOD: -21.40 )
BIOD' s 10-Year EPS Growth (3Y)(%) Range
Min: -44   Max: 113.9
Current: -21.4

-44
113.9
» BIOD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BIOD Guru Trades in Q1 2014

Jim Simons 184,895 sh (+27.08%)
Chuck Royce 20,100 sh (-49.75%)
» More
Q2 2014

BIOD Guru Trades in Q2 2014

Jim Simons 225,653 sh (+22.04%)
Chuck Royce 20,100 sh (unchged)
» More
Q3 2014

BIOD Guru Trades in Q3 2014

Chuck Royce 20,100 sh (unchged)
Jim Simons 63,300 sh (-71.95%)
» More
Q4 2014

BIOD Guru Trades in Q4 2014

Jim Simons 180,755 sh (+185.55%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BIOD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.60
BIOD's P/B is ranked higher than
94% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. BIOD: 1.60 )
BIOD' s 10-Year P/B Range
Min: 0   Max: 3.3
Current: 1.6

0
3.3
EV-to-EBIT -0.40
BIOD's EV-to-EBIT is ranked higher than
82% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIOD: -0.40 )
BIOD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.4

Current Ratio 12.20
BIOD's Current Ratio is ranked higher than
90% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. BIOD: 12.20 )
BIOD' s 10-Year Current Ratio Range
Min: 0.82   Max: 25.41
Current: 12.2

0.82
25.41
Quick Ratio 12.20
BIOD's Quick Ratio is ranked higher than
90% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. BIOD: 12.20 )
BIOD' s 10-Year Quick Ratio Range
Min: 0.82   Max: 25.41
Current: 12.2

0.82
25.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.50
BIOD's Price/Net Cash is ranked higher than
99% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 105.00 vs. BIOD: 1.50 )
BIOD' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 7.14
Current: 1.5

0.61
7.14
Price/Net Current Asset Value 1.50
BIOD's Price/Net Current Asset Value is ranked higher than
99% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. BIOD: 1.50 )
BIOD' s 10-Year Price/Net Current Asset Value Range
Min: 0.6   Max: 7.1
Current: 1.5

0.6
7.1
Price/Tangible Book 1.40
BIOD's Price/Tangible Book is ranked higher than
96% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. BIOD: 1.40 )
BIOD' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 6.82
Current: 1.4

0.56
6.82
Earnings Yield (Greenblatt) -247.70
BIOD's Earnings Yield (Greenblatt) is ranked lower than
72% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. BIOD: -247.70 )
BIOD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -413.5   Max: 5045.8
Current: -247.7

-413.5
5045.8

Analyst Estimate

Sep15 Sep16 Sep17
EPS($) -0.95 -1.57 -2.15
EPS without NRI($) -0.95 -1.57 -2.15

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BDQN.Germany,
Biodel, Inc., was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. The Company is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that might be safer, more effective and more convenient for patients. The Company develops its product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Its most advanced program involves developing proprietary formulations of injectable recombinant human insulin, or RHI, designed to be more rapid-acting than the 'rapid-acting' mealtime insulin analogs currently used to treat patients with Type 1 and Type 2 diabetes. In addition to its ultra-rapid-acting insulin formulation program, the Company is developing a liquid glucagon formulation for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.
» More Articles for BIOD

Headlines

Articles On GuruFocus.com
cooldecency99 note on BIOD May 01 2010 
Biodel Reports Third Quarter Fiscal Year 2009 Financial Results Aug 07 2009 
Biodel to Report Third Quarter Fiscal Year 2009 Results on August 7, 2009 Aug 03 2009 
Biodel Reports First Quarter Fiscal Year 2009 Financial Results and Clinical Update Feb 05 2009 
Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study Jan 30 2009 
Biodel Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results Dec 10 2008 

More From Other Websites
Nasdaq stocks posting largest volume increases Apr 17 2015
BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material... Apr 15 2015
Biodel Announces Pricing of Public Offering of Common Stock Apr 15 2015
BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 06 2015
Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior... Apr 06 2015
Biodel to Present at the 27th Annual ROTH Conference Mar 31 2015
Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment... Mar 31 2015
BIODEL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial... Mar 18 2015
BIODEL INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... Mar 16 2015
Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment... Mar 16 2015
Biodel to Present at the 27th Annual ROTH Conference Mar 04 2015
Biodel Reports First Quarter Fiscal Year 2015 Financial Results Mar 01 2015
BIODEL INC Financials Feb 19 2015
10-Q for Biodel, Inc. Feb 14 2015
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 12 2015
BIODEL INC Files SEC form 10-Q, Quarterly Report Feb 12 2015
Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog Feb 12 2015
Biodel Reports First Quarter Fiscal Year 2015 Financial Results Feb 12 2015
Q1 2015 Biodel Inc Earnings Release - 4:00 pm ET Feb 12 2015
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog Feb 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK